Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
SUMOylation is a reversible post-translational modification that regulates protein function through covalent attachment of small ubiquitin-like modifier (SUMO) proteins. The process of SUMOylating proteins involves an enzymatic cascade, the first step of which entails the activation of a SUMO protein through an ATP-dependent process catalyzed by SUMO-activating enzyme (SAE). Here, we describe the identification of TAK-981, a mechanism-based inhibitor of SAE which forms a SUMO-TAK-981 adduct as the inhibitory species within the enzyme catalytic site. Optimization of selectivity against related enzymes as well as enhancement of mean residence time of the adduct were critical to the identification of compounds with potent cellular pathway inhibition and ultimately a prolonged pharmacodynamic effect and efficacy in preclinical tumor models, culminating in the identification of the clinical molecule TAK-981.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Self-citationA small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment
Hyer, M. L., Milhollen, M. A., Ciavarri, J., Fleming, P., Traore, T., Sappal, D., Huck, J., Shi, J., Gavin, J., Brownell, J., et al. (2018) · Nature Medicine · doi:10.1038/nm.4474 · Cited by 447
Self-citationGinkgolic Acid Inhibits Protein SUMOylation by Blocking Formation of the E1-SUMO Intermediate
Fukuda, I., Ito, A., Hirai, G., Nishimura, S., Kawasaki, H., Saitoh, H., Kimura, K.-I., Sodeoka, M., & Yoshida, M. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.01.009 · Cited by 355
Li, Y.-J., Du, L., Wang, J., Vega, R., Lee, T. D., Miao, Y., Aldana-Masangkay, G., Samuels, E. R., Li, B., Ouyang, S. X., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.026 · Cited by 50
Cited by
Signalling mechanisms and cellular functions of SUMO
Vertegaal, A. C. O. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00500-y · Cited by 376
Metadata
- Authors
- Langston, S. P., Grossman, S., England, D., Afroze, R., Bence, N., Bowman, D., Bump, N., Chau, R., Chuang, B.-C., Claiborne, C., Cohen, L., Connolly, K., Duffey, M., Durvasula, N., Freeze, S., Gallery, M., Galvin, K., Gaulin, J., Gershman, R., Greenspan, P., Grieves, J., Guo, J., Gulavita, N., Hailu, S., He, X., Hoar, K., Hu, Y., Hu, Z., Ito, M., Kim, M.-S., Lane, S. W., Lok, D., Lublinsky, A., Mallender, W., McIntyre, C., Minissale, J., Mizutani, H., Mizutani, M., Molchinova, N., Ono, K., Patil, A., Qian, M., Riceberg, J., Shindi, V., Sintchak, M. D., Song, K., Soucy, T., Wang, Y., Xu, H., Yang, X., Zawadzka, A., Zhang, J., & Pulukuri, S. M.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-02-25
- Volume
- 64
- Issue
- 5
- Pages
- 2501-2520
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3131360915
- Cited by
- 203
- References
- 5
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer. https://app.cochat.ai/papers/10.1021/acs.jmedchem.0c01491
- The paper
- Langston, S. P., Grossman, S., England, D., Afroze, R., Bence, N., Bowman, D., Bump, N., Chau, R., Chuang, B.-C., Claiborne, C., Cohen, L., Connolly, K., Duffey, M., Durvasula, N., Freeze, S., Gallery, M., Galvin, K., Gaulin, J., Gershman, R., . . . Pulukuri, S. M. (2021). Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.0c01491
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.